Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome

被引：0
|
作者：
Marcel Merchan, Brayan [1 ]
Ortega, Margarita [1 ]
Jose Llamas-Poyato, Mara [2 ]
Cortes, Montserrat [3 ]
Arnan, Montserrat [4 ]
Cervero, Carlos [5 ]
Montoro, Julia [1 ]
Gimenez, Teresa [6 ]
Lopez, Mara [7 ]
Arenillas, Leonor [8 ]
Valcarcel, David [1 ]
机构：
[1] Univ Hosp Vall dHebron, Barcelona, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Fundacio Hosp Asil, Dept Hematol, Granollers, Spain
[4] Inst Catala Oncol Duran & Reynals, Barcelona, Spain
[5] Hosp Virgen La Luz, Dept Hematol, Cuenca, Spain
[6] Hosp Joan 23, Tarragona, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Hosp del Mar, GRENTHE, IMIM Hosp del Mar Res Inst, Barcelona, Spain
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
    Santini, Valeria
    Schemenau, Jennifer
    Levis, Alessandro
    Balleari, Enrico
    Sapena, Rosa
    Ades, Lionel
    Guerci, Agnes
    Beyne-Rauzy, Odile
    Gourin, Marie-Pierre
    Cheze, Stephane
    Stamatoullas, Aspasia
    Sanna, Alessandro
    Gioia, Daniela
    Cametti, Gianni
    Ferrero, Dario
    Raffoux, Emmanuel
    Rose, Christian
    Poloni, Antonella
    Prebet, Thomas
    Legros, Laurence
    Natarajan-Ame, Shanti
    Fenaux, Pierre
    Germing, Ulrich
    Dreyfus, Francois
    Park, Sophie
    [J]. BLOOD, 2013, 122 (13) : 2286 - 2288
  • [32] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Godley, Lucy
    Gabrail, Nashat Y.
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Stein, Karen
    Noble, Yvonne
    Kassalow, Laurent
    Kantarjian, Hagop M.
    [J]. BLOOD, 2011, 118 (21) : 1628 - 1629
  • [33] Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload
    Du, Yali
    Long, Zhangbiao
    Chen, Miao
    Han, Bing
    Hou, Bo
    Feng, Feng
    [J]. ACTA HAEMATOLOGICA, 2017, 138 (02) : 119 - 128
  • [34] Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
    Valcarcel, David
    Sanz, Guillermo
    Ortega, Margarita
    Nomdedeu, Benet
    Luno, Elisa
    Diez-Campelo, Maria
    Teresa Ardanaz, Maria
    Pedro, Carmen
    Montoro, Julia
    Collado, Rosa
    Andreu, Rafa
    Marco, Victor
    Teresa Cedena, Maria
    de Paz, Raquel
    Tormo, Mar
    Xicoy, Blanca
    Ramos, Fernando
    Bargay, Joan
    Gonzalez, Bernardo
    Brunet, Salut
    Antonio Munoz, Juan
    Gomez, Valle
    Bailen, Alicia
    Sanchez, Joaquin
    Merchan, Brayan
    del Canizo, Consuelo
    Vallespi, Teresa
    [J]. LANCET HAEMATOLOGY, 2015, 2 (06): : E260 - E266
  • [35] A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
    Raza, Azra
    Galili, Naomi
    Smith, Scott E.
    Godwin, John
    Boccia, Ralph V.
    Myint, Han
    Mahadevan, Daruka
    Mulford, Deborah
    Rarick, Mark
    Brown, Gail L.
    Schaar, Dale
    Faderl, Stefan
    Komrokji, Rami S.
    List, Alan F.
    Sekeres, Mikkael
    [J]. CANCER, 2012, 118 (08) : 2138 - 2147
  • [36] Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response
    Villegas, A.
    Arrizabalaga, B.
    Fernandez-Lago, C.
    Castro, M.
    Mayans, J. R.
    Gonzalez-Porras, J. R.
    Duarte, R. F.
    Remacha, A. F.
    Luno, E.
    Gasquet, J. A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 951 - 960
  • [37] Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate-1 risk patients with myelodysplastic syndromes
    Kalitin, Nikolay
    Dudina, Galina
    Kostritsa, Natalia
    Sivirinova, Anastasiya
    Karamysheva, Aida
    [J]. ONCOLOGY LETTERS, 2023, 25 (03)
  • [38] T CELL MEDIATED AUTOLOGOUS CYTOTOXICITY AGAINST HEMATOPOIETIC PRECURSOR CELLS IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
    Chamuleau, M. E. D.
    Westers, T. M.
    Groenland, J.
    Dreunen, L.
    Zevenbergen, A.
    Ossenkoppele, G. J.
    van de Loosdrecht, A. A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 275 - 275
  • [39] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    [J]. BLOOD, 2017, 130
  • [40] Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis
    Li, Liunan
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Kadia, Tapan
    Ravandi, Farhad
    Pierce, Sherry A.
    Wierda, William G.
    Abruzzo, Lynne V.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2010, 116 (21) : 1212 - 1212
12345